Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients-Reference-Cited by-同舟云学术

Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients

Published:2022-11 Issue:11 Volume:22 Page:2675-2681
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:American Journal of Transplantation

Author:

Benotmane Ilies^ORCID,Velay Aurélie,Gautier-Vargas Gabriela^ORCID,Olagne Jérôme^ORCID,Obrecht Augustin,Cognard Noëlle^ORCID,Heibel Françoise,Braun-Parvez Laura,Keller Nicolas,Martzloff Jonas,Perrin Peggy,Pszczolinski Romain,Moulin Bruno,Fafi-Kremer Samira^ORCID,Thaunat Olivier^ORCID,Caillard Sophie^ORCID

Publisher

Elsevier BV

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajt.17121

Reference14 articles.

1. An initial report from the French SOT COVID registry suggests high mortality due to COVID-19 in recipients of kidney transplants;Caillard;Kidney Int.,2020

2. Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients;Charmetant;Sci Transl Med.,2022

3. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses;Benotmane;JAMA.,2021

4. Antibody response to a fourth messenger RNA COVID-19 vaccine dose in kidney transplant recipients: a case series;Caillard;Ann Intern Med.,2022

5. REGEN-Cov antibody combination to prevent COVID-19 infection in kidney transplant recipient without detectable antibody response to optimal vaccine scheme;Ducloux;Kidney Int.,2022

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity;Vaccines;2024-06-18

2. Disability and Ableism in the COVID-19 Pandemic;The Social Epidemiology of the COVID-19 Pandemic;2024-06-13

3. Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study;Journal of Nephrology;2024-05-23

4. Investigation of severe acute respiratory syndrome coronavirus 2 infection status in solid organ transplant recipients treated with tixagevimab/cilgavimab;Journal of Infection and Chemotherapy;2024-05

5. Prevention and treatment strategies for kidney transplant recipients in the context of long-term existence of COVID-19;Frontiers in Medicine;2024-04-03